Table 2.
Study Population Characteristics
| Characteristic | No. | No. (%) or Median [Interquartile Range] |
|---|---|---|
| Age, years | 944 | 35 [25–49] |
| Female sex | 944 | 317 (34) |
| Non-White race | 943 | 751 (80) |
| Education, years | 943 | 9.0 (6.0–12.0) |
| Body mass index, kg/m2 | 944 | 20.2 [18.3–22.5] |
| Previous tuberculosis diagnosis | 935 | 142 (15) |
| Cavitation on chest X ray | 937 | 468 (50) |
| Smear positive | 943 | 768 (81) |
| Diabetes | 945 | 235 (25) |
| Human immunodeficiency virus infection | 938 | 182 (19) |
| Antiretroviral therapy experienced | 182 | 71 (39) |
| CD4 count, cells/mm 3 | 175 | 126 [54–274] |
| CD4 count <200 | 175 | 116 (66) |
| Viral load, copies/mL | 169 | 32,183 [309–205,226] |
| Viral load ≥200 | 169 | 130 (77) |
| Hemoglobin | 939 | 12.10 [10.7–13.3] |
| Any disease comorbiditya | 944 | 143 (15) |
| Alcohol use | 944 | |
| Current | 426 (45) | |
| Former | 366 (39) | |
| Never | 152 (16) | |
| Drug use | 943 | |
| Current | 117 (12) | |
| Former | 203 (22) | |
| Never | 623 (66) | |
| Tobacco use | 944 | |
| Current | 216 (23) | |
| Former | 273 (29) | |
| Never | 455 (48) | |
| NAT2 acetylator status | 944 | |
| Rapid | 78 (8) | |
| Intermediate | 382 (40) | |
| Slow | 484 (51) | |
| Treatment outcome category | 944 | |
| Cure | 386 (41) | |
| Treatment completion | 367 (39) | |
| Death | 29 (3) | |
| Treatment failure | 43 (4) | |
| Treatment incomplete | 56 (6) | |
| Not evaluated | 63 (7) | |
| Unsuccessful outcome | 191 (20) |
Italics indicate nonmutually exclusive groups, describing characteristics only among persons living with human immunodeficiency virus (HIV).
aExcluding diabetes and HIV infection.